Real‐world weight change among patients treated with glucagon‐like peptide‐1 receptor agonist, dipeptidyl peptidase‐4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence

AIMS: The study aims to examine real‐world weight change and the role of medication adherence among patients with type 2 diabetes who initiated one of three drug classes: glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), dipeptidyl peptidase‐4 inhibitor (DPP4) and sulfonylureas (SUs). MATERIALS AN...

Descripción completa

Detalles Bibliográficos
Autores principales: Carls, G. S., Tan, R., Zhu, J. Y., Tuttle, E., Yee, J., Edelman, S. V., Polonsky, W. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598021/
https://www.ncbi.nlm.nih.gov/pubmed/29071110
http://dx.doi.org/10.1002/osp4.116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598021/
https://www.ncbi.nlm.nih.gov/pubmed/29071110
http://dx.doi.org/10.1002/osp4.116

Ejemplares similares